# A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin

Study · id `cardio:ct-nct01628120` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01628120](<https://clinicaltrials.gov/study/NCT01628120>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01628120

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

## Technical summary

Registry record NCT01628120. Allocation not applicable; no masking; primary purpose treatment. Start 2012-05-31 (actual); primary completion 2015-02-13 (actual). Results posted on 2018-07-19.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 170 participants (enrolled count; ClinicalTrials.gov record NCT01628120, source copy `cardio:ctgov-nct01628120-2019-03-18`, retrieved 2026-10-26)
- Started: 2012-05-31 (actual) (ClinicalTrials.gov record NCT01628120, source copy `cardio:ctgov-nct01628120-2019-03-18`, retrieved 2026-10-26)
- Primary completion: 2015-02-13 (actual) (ClinicalTrials.gov record NCT01628120, source copy `cardio:ctgov-nct01628120-2019-03-18`, retrieved 2026-10-26)
- Completion: 2015-02-13 (actual) (ClinicalTrials.gov record NCT01628120, source copy `cardio:ctgov-nct01628120-2019-03-18`, retrieved 2026-10-26)
- Results first posted: 2018-07-19 (ClinicalTrials.gov record NCT01628120, source copy `cardio:ctgov-nct01628120-2019-03-18`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01628120, source copy `cardio:ctgov-nct01628120-2019-03-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01628120-2019-03-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
- Acronym: AiME - 04
- Condition: Chronic Renal Failure Requiring Hemodialysis
- Intervention (Biological): Epoetin Hospira
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: db67842dbee15561dc6b7123ba99228c8cb855abcaec1322c6bc0171ad2d6c56
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
